Loading…
Loading…
BICX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BICX and 80,000+ other tickers.
See exactly how BICX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BICX and 80,000+ other tickers.
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings…
Biocorrx Inc. (OTCMKTS:BICX - Get Free Report) was the target of a large decline in short interest in July. As of July 31st, there was short interest totaling 543 shares, a decline of 68.8% from the July 15th total of 1,741 shares. Approximately 0.0% of the shares of the stock are short sold. Based on
Biocorrx Inc. (OTCMKTS:BICX - Get Free Report) was the recipient of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,741 shares, an increase of ∞ from the June 30th total of 0 shares. Based on an average daily volume of 3,240 shares, the
IceCure Medical (NASDAQ: ICCM - Get Free Report) and Biocorrx (OTCMKTS:BICX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Risk and Volatility IceCure Medical has a beta
Biocorrx (OTCMKTS:BICX - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Profitability This table compares Biocorrx and GoodRx's net margins,
Biocorrx Inc. (OTCMKTS:BICX - Get Free Report)'s share price crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $0.32 and traded as high as $0.3995. Biocorrx shares last traded at $0.3995, with a volume of 4,789 shares. Biocorrx Stock Performance The company's 50